Clinical Trial Update: JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study [Phase 2]

View source ↗

Summary

A Phase II trial of JS212 plus JS111 for EGFR-mutant non-small cell lung cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JS111
• JS212

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations | Phase 2 | Status: NOT_YET_RECRUITING